ArticleImmunoTargets and therapy2024

Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study.

Murong Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.